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Abstract
Background Heart and pulmonary involvement is a leading
cause of systemic sclerosis (SSc)-related deaths.
Objectives The aim of our study was to assess if biochemical
markers of right ventricular (RV) overload, endothelial function
and collagen metabolism can predict RV dysfunction assessed
by Doppler echocardiography in SSc patients.
Methods We prospectively studied 111 consecutive patients
(101 F, 10 M, age 54.2±13.8 years) with diagnosed SSc (mean
disease duration 9.4±11.4 years) and a group of 21 age-matched
subjects (18 F, 3 M, age 49.3+10.5 years). We performed
transthoracic echocardiography (Phillips iE 33) and measured
serum endothelin-1 (ET-1), N-terminal pro-brain natriuretic
peptide (NT-proBNP), asymmetric dimethylarginine (ADMA),
endoglin and human tissue inhibitor of matrix metalloproteinase
(TIMP-1) concentration.
Results Median serum NT-proBNP level in SSc patients was
133.5 (range 21.86–17,670 pg/ml) and was significantly
higher than in controls (p =0.0002). Moreover, the median
serum ET-1 level of 1.49 (range 0.26–8.75 pg/ml) was higher
in SSc patients (p =0.002). However, no significant differ-
ences in ADMA, TIMP-1 and endoglin serum concentration
between SSc patients and controls were observed. Serum NT-
proBNP concentration correlated positively with echocardio-
graphic signs of RVoverload: tricuspid regurgitation pressure
gradient (r =0.38, p =0.0004) and RV Tei index (r =0.25, p =
0.01). ET-1 serum level correlated negatively with tricuspid
annular plane systolic excursion (r =−0.4, p =0.01) and posi-
tively with inferior vena cava diameter measured at expiration
(r =0.38, p =0.0002). The echocardiographic signs of RV
overload were significantly more pronounced in the highest
NT-proBNP tertile (>195 pg/ml) group than in the lowest one
(<88 pg/ml).
Conclusions Serum ET-1 and NT-proBNP, but not endoglin,
ADMA and TIMP-1 levels correlating with the echocardio-
graphic parameters of RVoverload, can be considered as non-
invasive indicators of RV dysfunction in SSc patients.
Keywords Biomarkers . Echocardiography . Pulmonary
hypertension . Systemic sclerosis
Introduction
Systemic sclerosis (SSc) is a connective tissue disease char-
acterized by vascular inflammation and immunologically
mediated fibrosis of the skin and various organs including
the cardiovascular system. Cardiopulmonary complications
adversely influence the prognosis in SSc patients [1, 2].
According to the recent systematic review and meta-analysis
of cohort studies, the pooled standardized mortality ratio
among SSc patients was 3.5 (95 % CI 3.03–4.11), and mor-
tality did not significantly change over the past 40 years [3].
Komocsi et al. analysed 18 studies comprising a total of
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12,829 SSc patients. The reported causes of death were
19.7 % cardiac, 16.8 % interstitial pulmonary disease and
13.1 % pulmonary hypertension [4].
Potentially, identification of noninvasive predictors of right
ventricular (RV) dysfunction may allow early detection of
cardiac involvement and may help to select patients for further
invasive evaluation [5]. Echocardiography is a widely avail-
able noninvasive diagnostic tool for RV dysfunction detec-
tion. Recent guidelines of the European Society of Cardiology
(ESC) for the diagnosis and treatment of pulmonary hyper-
tension suggest considering annual echocardiographic assess-
ment of SSc patients even if they remain asymptomatic [6].
However, over the last years, a variety of biochemical bio-
markers have been identified to be important in the assessment
of SSc patients. There is increasing evidence that N-terminal
pro-brain natriuretic peptide (NT-proBNP) and endothelin-1
(ET-1) serum levels are elevated in patients with SSc and RV
dysfunction [7–9]. Moreover, asymmetric dimethylarginine
(ADMA), a parameter of endothelial dysfunction, and
endoglin, an important modulator of endothelial vasomotor
tone, also have been found to be elevated in this group of
patients [10, 11]. Interestingly, it was observed that the serum
concentration of the tissue inhibitor of metalloproteinase 1
(TIMP-1), a marker of decreased collagen metabolism, is
increased in patients with SSc and correlates with ADMA
serum level which may suggest an association between endo-
thelial dysfunction and matrix remodelling [12].
The aim of our study was to assess if biochemical markers
of right ventricular overload, endothelial dysfunction and
collagen metabolism can predict RV impairment assessed by
Doppler echocardiography in SSc patients.
Materials and methods
One hundred eleven consecutive patients with confirmed SSc
(101 females, 10 males, mean age 54.2±13.7) with mean time
of 9.4±11.4 years from SSc diagnosis were prospectively
included into the study. SSc was diagnosed according to the
American College of Rheumatology criteria [13]. Patients
with diffuse SSc or limited scleroderma were recruited.
Forty-seven (42 %) patients were classified as having diffuse
SSc, while 64 (58 %) had limited SSc. Clinical characteriza-
tion of patients with SSc was performed according to the
European Scleroderma Trial and Research recommendations
[14]. Evaluation of signs and symptoms of SScwas performed
in all patients at the onset of the study. In all SSc patients,
pulmonary involvement was assessed by chest radiography,
HRCT (Toshiba Aquilion 64), pulmonary function testing and
measurement of single-breath diffusing lung capacity for car-
bon monoxide (DLCO) (Sensor Medics, Yorba Linda, USA).
Patients with cardiovascular disorders such as coronary
artery disease (angina pectoris, previous myocardial infarction,
ECG and/or echocardiographic signs ofmyocardial ischaemia),
atrial fibrillation, cardiac pacing, significant valvular abnormal-
ities and left ventricular (LV) hypertrophy (intraventricular
septum and posterior wall >11 mm in echocardiographic ex-
amination) were excluded from the current study. Moreover,
SSc patients with significant pulmonary functional abnormali-
ties (defined by forced vital capacity [FVC], total lung capacity
[TLC] or forced expiratory volume in 1 s [FEV1] <60 % of
predicted) were also not included. We also did not include
patients with significant fibrotic changes in the lung by high-
resolution computed tomography (Kazerooni fibrosis score
≥16). An impaired renal function with creatinine clearance
calculated by the Modification of Diet in Renal Disease
Study Group formula below 60 ml/min/1.73 m2 was also an
exclusion criterion.
We assessed 21 age- and sex-matched subjects (18 females,
3 males, mean age 49.3±10.5 years) as a control group.
Special attention was directed to selection of the control group
with the same profile of coexisting systemic hypertension and
the same cardiologic therapy used as the SSc patients. These
subjects had no data for pulmonary diseases and presented no
echocardiographic evidence of structural heart disease.
All patients and control subjects gave informed consent,
and the protocol of the study was approved by the local
Institutional ethics Committee (Medical University of Warsaw
ethics Committee, no. KB66/2006).
Serological parameters
Standard techniques were used to screen all patients for the
following serological markers: anti-nuclear antibody (ANA),
anti-centromere antibody (ACA) and anti-nucleolar antibody
(ANoA) by indirect immunofluorescence on monkey oesoph-
agus at a dilution of serum of 1:20 and on Hep 2 cell line at a
dilution of 1:40. Anti-extractable nuclear antigen antibodies,
including Scl-70 antibodies, were identified by double
immunodiffusion.
Blood sampling and assays
At the same day when echocardiography was performed,
fasting blood samples were collected by venipuncture and
centrifuged. Sera were stored at −70 °C until assayed.
The concentration of NT-proBNP was analysed on an
Elecsys 2010 automatic analyzer (Roche Diagnostics, Basel,
Switzerland). Serum NT-proBNP concentration higher than
125 pg/ml was regarded as abnormal as indicated by the
producer.
The concentration of endothelin-1 was measured with the
use of the QuantiGlo Human Endothelin-1 immunoassay kit
(cat. no. QET00B, R&D Systems, Inc., Minneapolis, MN,
USA) according to the manufacturer’s protocol. A Fluoroskan
Ascent FL microplate luminometer (Thermo Labsystems Oy,
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Helsinki, Finland) was used to measure the intensity of
the light emitted, and Ascent Software, v. 2.6, was used
for creation of standard curves, curve fitting and calcula-
tions of concentrations. To detect endoglin, a commercial
immunoenzymatic kit, QuantiGlo Human Endoglin/CD
105 immunoassay kit (cat. no. DNDG00, R&D Systems,
Inc., Minneapolis, MN, USA), was used. The concentration of
ADMAwas measured using a commercial immunoenzymatic
kit (ADMA Elisa Kit, Immunodiagnostik AG, Germany). A
commercial immunoenzymatic kit, Human TIMP-1 Immuno-
assay (R&D Systems, Inc., Minneapolis, MN, USA), was
used to detect TIMP-1.
Tests detecting endoglin, ADMA and TIMP-1 were based
on a solid double-antibody sandwich ELISA. Sera were added
to microwells precoated with antibodies against detected an-
tigen. All samples were assayed in duplicates. In the positive
cases, antigen–antibody complex reacted with peroxidase-
labelled antihuman IgG conjugate. Using H2O2/TMB as sub-
strate, the enzymatic activity of peroxidase was measured at
450 nm with the use of the automated reading system Asys
UVM 340. All the results were referred to the standard curve.
The standards were provided for the generation of a semi-
logarithmic reference curve. Immunoenzymatic assays were
performed blindly by a laboratory technician according to the
manufacturer instruction.
Echocardiography
Echocardiographic examination was performed with Philips
iE 33 (Andover, Md., USA) with 2.5–3.5-MHz transducers.
Patients were examined in the left lateral position. The dimen-
sions of the right and left ventricles were measured in the
parasternal long-axis view and apical four chamber view in
late diastole defined by the R wave of continuously monitored
ECG lead. From the subcostal approach, vena cava dimen-
sions at spontaneous inspiration and expiration were mea-
sured. After the recording of the tricuspid valve peak systolic
velocity with continuous-wave Doppler echocardiography,
the tricuspid regurgitation peak gradient (TRPG) was calcu-
lated according the simplified Bernoulli equation. Pulmonary
hypertension (PH) was suspected according to ESC criteria
when TRPG >31 mmHg (tricuspid regurgitant velocity
>2.8 m/s) [6]. Patients in whom (PH) was suspected were
directed to right heart catheterisation. Acceleration time of
pulmonary ejection (AcT) was measured using pulse wave
Doppler with sample volume placed in the RV outflow tract
just below the pulmonary valve.Measurements were averaged
over five consecutive heart cycles. The Tei index for the right
ventricle was calculated by dividing the sum of RV
isovolumetric contraction and relaxation time by RV ejection
time, as has been described previously [15]. In order to assess
the right ventricular function using one-dimensional M-mode
echocardiography, the tricuspid annular peak systolic
excursion (TAPSE) was measured. The LV ejection frac-
tion (EF) was calculated according to the modified
Simpson rule using apical four- and two-chamber views
[16].
Six-minute walk test
The 6-min walk test (6MWT) was performed on a level
hallway surface in accordance with the American Thoracic
Society guidelines [17].
Statistical analysis
Data characterized by a normal distribution are expressed as a
mean followed by a standard deviation. Biochemical param-
eters are expressed both as a mean followed by a standard
deviation and as a median with a range. Patients with SSc and
controls were compared with the Wilcoxon test depending on
the character of parameter distribution. For categorical vari-
ables, the differences between the groups were compared with
Chi squared test or Fisher’s exact test. Correlations between
echocardiographic and biochemical variables were evaluated
by Spearman’s correlation coefficients. Receiver-operating
characteristic (ROC) analysis was performed for the selection
of the optimal cut-off value of the NT-proBNP and ET-1 levels
for the prediction of TRPG >31 mmHg and RV Tei index
>0.4.
An analysis was performed using a statistical software
package (SAS 9.2). p <0.05 was considered statistically
significant.
Results
A total of 111 SSc patients and 21 control subjects were
enrolled in this study. The general characteristics of the study
population and control group are summarized in Table 1.
Treatment
Thirty-one (28 %) SSc patients were treated with the
angiotensin-converting enzyme inhibitors (ACE-I), while






Age (years) 54.2±13.7 49.3±10.5 NS
Gender (F/M) (no.) 101/10 18/3 NS
Body surface area (m2) 1.73±0.26 1.72±0.18 NS
Heart rate (bpm) 73.47±9.45 76.21±12.38 NS
Systemic hypertension (%) 37 (33 %) 6 (29 %) NS
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seven of them (6 %) were treated with angiotensin II
receptor antagonists. Ten SSc patients (9 %) must have
been treated with beta blockers, because they had ongoing
tachycardia. Sixteen SSc patients (14 %) also received
diuretics, and 27 (24 %), calcium channel blockers. Due
to the progression of SSc, 15 (13.5 %) patients received
immunosuppressant agents (glucocorticoids and cyclo-
phosphamide). Also, the control patients received phar-
macological treatment, but we did not find significant
differences in the use of the cardiological drugs between
the SSc and control groups. The main clinical, pulmonary
function and serological findings of SSc patients are shown
in Table 2.
Echocardiography data
In Table 3, the echocardiographic parameters and 6MWT data
in the SSc group and controls are presented. The left ventric-
ular dimension was similar in both groups; however, the left
ventricular systolic function assessed with EF was statistically
lower in SSc patients than in controls. Interestingly, echocar-
diography revealed significant differences in RV morphology
and function. TRPG values exceeding 31 mmHg at rest,
suggesting the possibility of PH, were found in 22 (20 %)
SSc patients, while in all controls, it was below this value. The
SSc group presented also other echocardiographic signs of RV
overload (Table 3). As we expected, SSc patients presented
markedly shorter 6MWT distance than controls (515±102 vs
563±60 m p =0.03).
Plasma biomarker levels
Biochemical parameters in SSc patients and controls are
presented in Table 4. Serum NT-proBNP levels exceeded the
reference value (125 pg/ml) in 50 (45 %) SSc patients. The
median serum NT-proBNP level in SSc patients was 133.5
(range 21.86–17,670 pg/ml). In all controls, the NT-proBNP
serum concentration was below the reference value and was
significantly lower than in SS patients. Moreover, in SSc
patients, the mean serum ET-1 level was 1.86±1.4 pg/ml
(median value 1.49, range 0.26–8.75 pg/ml) and was signifi-
cantly higher than in controls (p =0.002). However, no signif-
icant differences in other biomarker serum concentrations
between SSc patients and controls were observed (Table 4).
Serum NT-proBNP concentration correlated positively
with echocardiographic indices of RV overload: TRPG (r =
0.38, p =0.0004) and RV Tei index (r =0.25, p =0.01). ET-1
serum level correlated negatively with TAPSE (r =−0.4, p =
0.01) and positively with inferior vena cava (IVC) diameter
measured at expiration (r =0.38, p =0.0002).
We divided the SSc group according to the NT-proBNP
serum tertiles. Table 5 presents clinical and echocardiographic
parameters in the lowest and highest tertile group of patients
according to the NT-proBNP levels.
The echocardiographic signs of RVoverload were signifi-
cantly more pronounced in the highest NT-proBNP tertile
group than in the lowest one. Also, the 6MWT distance was
significantly shorter in this group.
Table 2 Clinical, pulmonary function and serological data of 111 SSc
patients
Characteristics Mean
Disease duration (years) 9.4±11.4
Median, range 5.0 (1–25)
Rodnan score 6.4±6.7
Median, range 4.0, 1–35
FVC, % predicted 100.4±18.3
FEV1, % predicted 94.7±19.7
FEV1/FVC, % predicted 79.8±8.2
TLC, % predicted 101.9±17.5
DLCO, % predicted (n =59) 70.7±19.1




ANA positive 105 95
ACA positive 34 31
Anti-Scl 70 positive 56 50
FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, TLC
total lung capacity, DLCO diffusion capacity of the lung for carbon
monoxide







EF (%) 65.05±5.1 67.57±2.52 0.01
RV 4 chambers (mm) 28.92±5.36 25.33±4.07 0.0029
RV/LV 4 chambers 0.73±0.12 0.66±0.08 0.01
TAPSE (mm) 22.2±3.23 24.14±2.37 0.01
RV Tei index 0.37±0.08 0.29±0.02 <0.0001
AcT (ms) 116.46±21.11 134.76±16 0.0006
TRPG (mmHg) 26.67±6.97 17.78±4.07 <0.0001
Pulmonary trunk (mm) 19.09±2.28 17.8±1.43 0.009
IVC expiration (mm) 13.74±2.93 9.33±1.15 <0.0001
IVC inspiration (mm) 13.52±3.11 13.42±1.59 NS
6MWT (m) 515±102 563±60 0.03
EF ejection fraction, RV right ventricle, LV left ventricle, TAPSE tricus-
pid annulus plane systolic excursion, AcT acceleration time of pulmonary
ejection, TRPG tricuspid regurgitant peak gradient, IVC inferior vena
cava, 6MWT 6-min walking test
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ROC analysis in order to define the optimal serum NT-
proBNP level for TRPG >31 mmHg detection was also
performed. The area under the curve (AUC) was 0.779. A
cut-off value of 195 pg/ml showed sensitivity of 75 %, spec-
ificity of 67 %, positive predictive value (PPV) of 88 % and
negative predictive value (NPV) of 43 % for SSc-related PH.
We also performed ROC analysis to define the optimal
serum NT-proBNP level for Tei index >0.4 detection. The
AUC was 0.681. A cut-off value of 215 pg/ml revealed
sensitivity of 79 %, specificity of 57 %, PPV of 86 % and
NPVof 44 % for Tei index >0.4 detection.
A similar analysis was performed to define the optimal
serum ET-1 level for Tei index >0.4 detection. The AUC
was 0.618. A cut-off value of 1.85 pg/ml showed sensitivity
of 69 %, specificity of 52 %, PPVof 83 % and NPVof 34 %
for Tei index >0.4.
Discussion
Pulmonary hypertension is the most common cause of
scleroderma-related morbidity and mortality [18, 19]. Early
detection of RV dysfunction even in asymptomatic patients
seems to be important for their prognosis. In the present study,
we assessed several biochemical biomarkers and their relation
with echocardiographic parameters of RV dysfunction.
According to the recent ESC guidelines, TRPG >31 mmHg
may suggest PH [6]. In our study, TRPG was significantly
higher in SSc patients than in the control group. Moreover, in
SSc patients, we found both the RV and pulmonary trunk
diameters to be significantly increased, which may suggest
RV pressure overload. RV Tei index, an accepted global
ventricular function parameter, was markedly increased in
SSc patients indicating decreased RV performance [6, 20].
Tei et al. reported a significant increase in the mean value of
the Tei index in 26 patients with pulmonary arterial hyperten-
sion (PAH) compared to 37 controls. They also revealed the
prognostic value of this parameter [15]. Similar data were
published by Yeo et al. [21]. Sebbeg et al. reported that
changes in RV Tei index correlated with the changes in
clinical status in PH patients [22]. Hsiao et al. reported in-
creased RV Tei index in 40 SSc patients compared to 45
controls [23]. Another echocardiographic parameter of RV
systolic function impairment which we assessed in the present
study was TAPSE. In our SSc group of patients, the mean
value of TAPSE was significantly decreased compared to
controls. In total, there have been >40 studies with >2,000
normal subjects evaluating the utility of TAPSE [20]. To date,
there are only a few studies including TAPSE assessment in
the SSc population. Mathai et al., in the group of 50 SSc-
related PAH subjects, revealed that TAPSE is a robust param-
eter of RV function and strongly predicts survival in this group
[24]. Moreover, in our study, we found shorter AcT in SSc
patients than in controls suggesting disturbed coupling to the
pulmonary arterial bed. Our findings therefore confirm that
SSc patients can be characterized by RV dysfunction in echo-
cardiography and suggest that the use of novel indicators such
as TAPSE and RV Tei index can be useful in evaluating the
RV function in SSc patients. A 6MWT is recommended for
prognostic evaluation in PAH patients, because it is a strong
and independent mortality predictor and correlates with the
NYHA/WHO classification [25]. As we expected, in our
study, patients with SSc had a statistically significant shorter
6MWT distance than the control group (p =0.03) which is in
accordance with the previous studies [26, 27]. What is new is
that the mean 6MWT distance was significantly shorter in
the highest NT-proBNP tertile group than in the lowest
one (p =0.04), pointing that the distance achieved during the
6MWT not only is depending on the patient’s joint and
muscle problems but also is the indicator of heart involvement
in SSc patients
The main aim of our study was to assess if biochemical
markers of right ventricular overload, endothelial dysfunction
and collagen metabolism can predict RV dysfunction assessed






NT-proBNP (pg/ml) 621.02±2,565.34 62.65±26.94 0.0002
Median, range 133.5, 21.86–17,670 62.2, 30.8–116
Endothelin-1 (pg/ml) 1.86±1.4 1.23±0.6 0.002
Median, range 1.49, 0.26–8.75 1.16, 0.76–3.19
ADMA (μmol/l) 0.45±0.14 0.46±0.09 NS
Median, range 0.45, 0.23–0.99 0.44, 0.34–0.67
Endoglin (ng/ml) 3.43±0.97 3.95±1.5 NS
Median, range 3.22, 2.16–6.55 4.44, 1.29–6.14
TIMP-1 (ng/ml) 167±63.1 182.8±28.8 NS















Age (years) 48.29±13.24 64.40±9.87 <0.0001
BSA (m2) 1.78±0.23 1.63±0.18 0.01
AcT (ms) 123.54±22.77 112.34±20.35 0.04
RV Tei index 0.34±0.07 0.39±0.1 0.03
TRPG (mmHg) 23.7±4.25 30.0±9.14 0.004
IVC inspiration (mm) 13.16±3.0 15.09±2.66 0.003
6MWT (m) 534±106 456±96 0.04
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by Doppler echocardiography. We found that serum levels of
NT-proBNP and ET-1 were significantly higher in SSc
patients than in controls. Moreover, we revealed that SSc
patients with serum NT-proBNP levels in the highest tertile
had more pronounced RV dysfunction than the group in the
lowest tertile. NT-proBNP serum concentration correlated
positively with echocardiographic indices of RV overload:
TRPG and RV Tei index. Williams et al. in the group of 109
SSc patients reported significantly higher serum NT-proBNP
level in 68 patients with PAH than without PAH (1,474 vs
139 pg/ml, p =0.002). They also found significant correlations
between NT-proBNP serum level and mean pulmonary artery
pressure (r =0.62, p <0.0001) and pulmonary vascular resis-
tance (r =0.81, p <0.0001) [28]. Dimitroulas at al. analysed
data of 66 patients with SSc. Similar to our findings, they
revealed significantly increased serum NT-proBNP level in
SSc patients with echocardiographic signs of PH (370.5
[224.9–606.7] vs 256.1 [197.3–351.7]fmol/l, p =0.012)
(179). NT-proBNP (OR per 10 fmol/l increase 1.03; 95 %
CI 1.00–1.05) was the univariate correlate of the presence of
PH [5].
The authors of recent published results of the DETECT
study proposed the first evidence-based detection algorithm
for PAH in SSc. According to this data, serum NT-proBNP
level is a useful marker in the algorithm for early identification
of PAH in a mildly symptomatic population [29].
In our SSc group of patients, the ROC analysis revealed
that the serum NT-proBNP level 195 pg/ml showed a sensi-
tivity of 75 % and a specificity of 67 % for SSc-related RV
overload. Oravec et al. in the group of 119 SSc patients
reported that the serumNT-proBNP level 157.8 pg/ml showed
100 % sensitivity, 72.3 % specificity, 39.1 % PPVand 100 %
NPV for detected PH [30]. We also revealed using the ROC
analysis that serum NT-proBNP level is useful in identifica-
tion of RV Tei index >0.4. Moreover, the serum ET-1 level
1.85 pg/ml showed 69 % sensitivity and 52 % specificity for
RV Tei index >0.4 detection. To our knowledge, this is the
first such analysis in SSc patients.
We did not find significant differences in serum levels of
ADMA, endoglin and TIMP-1 between SSc patients and
controls. These biomarkers also did not correlate with echo-
cardiographic indices of RV overload. Blaise et al. revealed
increasedmeanADMA concentrations in 39 SSc patients than
in controls (0.68±0.12 vs 0.62±0.12 μM, p =0.002) [12].
Dimitroulas et al. reported higher plasma ADMA levels in
SSc patients with PH compared to those without PH (p =
0.0008) [5]. In contrast, Wipff et al. did not find significant
differences in serum ADMA levels between SSc and controls
(0.83±0.35 vs 0.89±0.30 μmol/l, NS) [11]. There are several
reports that serum levels of endoglin, a parameter of endothe-
lial dysfunction, can be elevated in SSc patients [11, 31].
Some authors revealed that TIMP-1, a marker of decreased
collagen metabolism, is increased in patients with SSc [12,
32]. Non-elevated levels of ADMA and endoglin in our group
of SSc patients may be due to the fact that only 20 (22 %) of
them presented RV overload (TRPG >31 mmHg). Also, no
significant differences in mean serum concentration of TIMP-
1 between SSc and control group can result from mild and
moderate stages of SSc. Maybe after long-term follow-up and
disease progression will the differences between biomarkers
reach statistical significance.
This is a first study that explores the relationship between
five different biomarkers and impaired RV function in SSc.
Additional investigations in prospective studies are warranted
to confirm our findings.
Limitations of the study
In our study, we did not estimate the impact of the lung
function indices on the echocardiographic and biochemical
parameters. To minimize the influence of the bronchial
obstruction, we excluded patients with impaired results of
spirometry. Also, more than 30 % of SSc patients had mild to
moderate lung fibrosis, which might have had some influence
on the results.
Conclusions
Serum ET-1 and NT-proBNP, but not ADMA, endoglin and
TIMP-1 levels correlatingwith the echocardiographic parameters
of RVoverload, can be considered as noninvasive indicators of
RV dysfunction in SSc patients.
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